- ProMIS Neurosciences (PMN) has appointed Gail M. Farfel, Ph.D., as Chief Executive Officer, effective September 19, 2022
- Gail M. Farfel, Ph.D., is an accomplished pharma development and regulatory leader with over 25 years of experience in large and small pharma
- Prior to joining ProMIS, Gail served as Executive Vice-President and Chief Development Officer of Zogenix Inc
- Gail obtained her Ph.D. in neuropsychopharmacology from the University of Chicago
- ProMIS Neurosciences, Inc. is a development-stage biotechnology company
- ProMIS Neurosciences Inc. (PMN) opened trading at C$ 7.22
ProMIS Neurosciences (PMN) has appointed Gail M. Farfel, Ph.D., as Chief Executive Officer, effective September 19, 2022.
“The past 18 months have been transformative for ProMIS,” stated Eugene Williams, ProMIS Chairman and Co-Founder.
“During this period, we achieved strong capital formation led by a prominent group of Boston-based investors and, with tremendous shareholder support, accomplished our goal of listing ProMIS on Nasdaq. We also have expanded and strengthened our Board of Directors with the addition of three industry veterans as Independent Directors: Josh Mandel-Brehm, Dr. Maggie Shafmaster, and Neil Warma. Our amyloid oligomer-selective lead therapeutic antibody candidate for Alzheimer’s disease (AD), PMN310, is poised for IND submission by year-end, and we have continued to expand our portfolio of antibody and therapeutic vaccine candidates targeting other neurodegenerative diseases. We have also continued to expand our strong management team, having added Dr. Larry Altstiel as Chief Medical Officer and, in late 2021, Gavin Malenfant as Chief Operating Officer.
Perhaps the most important of these transformational accomplishments is bringing on Gail Farfel as CEO.”
“Gail has a distinguished track record of accomplishments in both large pharma and biotech, and she has invaluable expertise in neurologic disease drug development. After an extensive search, we are confident that under Gail’s leadership, ProMIS can achieve its tremendous potential. ProMIS’ Board and management welcome her to the CEO role as we work to complete the transition to a clinical-stage, multi-product, Nasdaq listed company,” added Gene Williams.
Gail Farfel remarked,
“I am honoured and excited to take on the role of CEO at ProMIS. There is a rapidly growing number of emerging companies in the neurology space, an area of tremendous growth, but I feel ProMIS is uniquely well-positioned to make a meaningful contribution to the field. A very strong foundation has been built, anchored on a unique discovery platform, giving us the potential to advance what we believe to be differentiated products to address urgent unmet medical needs. I look forward to working with this impressive team and to providing my leadership as ProMIS seeks to become a clinical phase biotechnology company with multiple development opportunities.”
Gail M. Farfel, Ph.D., is an accomplished pharma development and regulatory leader with over 25 years of experience in large and small pharma, including venture-backed and public companies. Gail has a strong record of accomplishments in neuropsychiatric clinical development and global regulatory submissions, including multiple successful investigational new drug (IND), new drug application (NDA) and marketing authorization application (MAA) registrations, U.S. Food and Drug Administration (FDA) Advisory Committee experience, and three successful global “first” indications.
Prior to joining ProMIS, Gail served as Executive Vice-President and Chief Development Officer of Zogenix Inc, where she delivered successful Phase 3 programs in Dravet syndrome and Lennox-Gastaut syndrome (LGS), leading to approvals from the FDA (Dravet and LGS) and European Medicines Agency (EMA) approval for Fintepla in 2020 and 2021. Further, while an executive at Zogenix, she supported capital raises in excess of US $700M; the acquisition of Modis Therapeutics; the alliance with Tevard Biosciences; and the acquisition of Zogenix by UCB Pharma in March 2022. In her earlier career, Gail held positions of increasing responsibility at SmithKline Beecham, Pfizer, Novartis, G. Meredith Consulting and Marinus Pharmaceuticals. Gail obtained her Ph.D. in neuropsychopharmacology from the University of Chicago.
ProMIS Neurosciences, Inc. is a development-stage biotechnology company.
ProMIS Neurosciences Inc. (PMN) opened trading at C$ 7.22.
